In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin

Diagnostic Microbiology and Infectious Disease

Volumn 71, Issue 4, 2011, Pages 470-473

  Vidaillac, Céline ^a,d   Parra Ruiz, Jorge ^a,e   Rybak, Michael Joseph ^a,b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

^d NANCY UNIVERSITÉ   (France)

^e Infectious Diseases Unit   (Spain)

Author keywords

Daptomycin nonsusceptible MRSA; Oritavancin; Susceptibility

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFOXITIN; DAPTOMYCIN; ORITAVANCIN; OXACILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE; TIME;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; GLYCOPEPTIDES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS;

EID: 82555169543     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.09.002     Document Type: Article

References (23)

1. Arhin F.F., McKay G.A., Beaulieu S., Sarmiento I., Parr T.R., Moeck G. Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 2009, 65:207-210.
2. Bouza E., Burillo A. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains. Int. J. Antimicrob. Agents 2010, 36:401-407.
3. Cha R., Grucz R.G., Rybak M.J. Daptomycin dose-effect relationship against resistant Gram-positive organisms. Antimicrob. Agents Chemother. 2003, 47:1598-1603.
4. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2009, CLSI, Wayne, PA. 9th ed.
5. Cui L.Z., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2006, 50:1079-1082.
6. Domaracki B.E., Evans A.M., Venezia R.A. Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 2000, 44:1394-1396.
7. Domenech O., Dufrene Y.F., Van Bambeke F., Tukens P.M., Mingeot-Leclercq M.P. Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus. Biochim. Biophys. Acta 2010, 1798:1876-1885.
8. Jones R.N. Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol Infect 2008, 14(Suppl 2):3-9.
9. Joukhadar C., Pillai S., Wennersten C., Moellering R.C., Eliopoulos G.M. Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 2010, 54:773-777.
10. Leach K.L., Brickner S.J., Noe M.C., Miller P.F. Linezolid, the first oxazolidinone antibacterial agent. Ann. N. Y. Acad. Sci. 2011, 1222:49-54.
11. Liu C., Bayer A., Cosgrove S.E., Daum R.S., Fridkin S.K., Gorwitz R.J., Kaplan S.L., Karchmer A.W., Levine D.P., Murray B.E., J Rybak M., Talan D.A., Chambers H.F. Clinical practice guidelines by the IDSA for the treatment of MRSA infections in adults and children. Clin. Infect. Dis. 2011, 52:1-38.
12. McKay G.A., Beaulieu S., Arhin F.F., Belley A., Sarmiento I., Parr T., Moeck G. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J. Antimicrob. Chemother. 2009, 63:1191-1199.
13. NCCLS Methods for determining bactericidal activity of antimicrobial agents. Approved guideline. NCCLS document M26-A 1999, NCCLS, Wayne, PA.
14. Rong S.L., Leonard S.N. Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance. Ann. Pharmacother. 2010, 44:844-850.
15. Rose W.E., Rybak M.J., Kaatz G.W. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J. Antimicrob. Chemother. 2007, 60:334-340.
16. Rossolini G.M., Mantengoli E., Montagnani F., Pollini S. Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents. Curr. Opin. Microbiol. 2010, 13:582-588.
17. Saravolatz L.D., Pawlak J., Johnson L.B. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int. J. Antimicrob. Agents 2010, 36:69-72.
18. Sieradzki K., Leski T., Dick J., Borio L., Tomasz A. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J. Clin. Microbiol. 2003, 41:1687-1693.
19. Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J., Gorbach S.L., Hirschmann J.V., Kaplan E.L., Montoya J.G., Wade J.C. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 2005, 41:1373-1406.
20. Vidaillac C., Leonard S.N., Rybak M.J. In-Vitro activity and aminoglycoside synergy of ceftaroline against hospital-acquired (HA) methicillin-resistant Staphylococcus aureus (MRSA) isolates. Sous presse. Int. J. Antimicrob. Agents 2010, 35:527-530.
21. Vidaillac C., Murray K., Rybak M. Evaluation of vancomycin and oxacillin combination against mecA positive vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA) with varying oxacillin susceptibility 2010.
22. Wootton M., Howe R.A., Hillman R., Walsh T.R., Bennett P.M., MacGowan A.P. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 2001, 47:399-403.
23. Zhang K., McClure J.A., Elsayed S., Louie T., Conly J.M. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 2005, 43:5026-5033.